mRNA technology clinical pipelines worldwide by therapy area and stage 2021
As of July 2021, around three percent of mRNA prophylactic vaccines worldwide were approved or received an emergency use authorization, while around 25 percent of therapeutic vaccines were in phase I of clinical trial. This statistic illustrates the share of mRNA technology in clinical pipelines worldwide as of July 2021, by therapy area and stage of development.